Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director · Executive Chair of the Board | March 10, 2024 | March 12, 2024 |
| STRYKER CORPSYK · Entity 369 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 432,266.333 |
Ending reported balance
After 2024-03-10 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2024-03-10 · Exercise / conversion · Acquired 23,409 · Balance 390,904.333 F1: Represents vesting of one-quarter of market share units granted on March 10, 2020. Row 2 · 2024-03-10 · Other · Disposed 3,687 · Balance 387,217.333 F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor. Row 3 · 2024-03-10 · Tax withholding · Disposed 10,088 · Balance 377,129.333 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2024-03-10 · Exercise / conversion · Acquired 23,817 · Balance 400,946.333 F4: Represents vesting of one-quarter of market share units granted on March 10, 2021. Row 5 · 2024-03-10 · Other · Disposed 4,104 · Balance 396,842.333 F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor. Row 6 · 2024-03-10 · Tax withholding · Disposed 10,084 · Balance 386,758.333 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2024-03-10 · Exercise / conversion · Acquired 142,904 · Balance 529,662.333 F5: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award. Row 8 · 2024-03-10 · Other · Disposed 49,745 · Balance 479,917.333 F6: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Row 9 · 2024-03-10 · Tax withholding · Disposed 47,651 · Balance 432,266.333 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2024-03-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-10 · Exercise / conversion · Disposed 23,409 · Balance 0 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1: Represents vesting of one-quarter of market share units granted on March 10, 2020. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2025-03-10 | Direct | 23,818 |
Reported balance
After 2024-03-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-10 · Exercise / conversion · Disposed 23,817 · Balance 23,818 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4: Represents vesting of one-quarter of market share units granted on March 10, 2021. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 44,429 |
Reported balance
After 2024-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-10 · Other · Disposed 22,214 · Balance 44,429 F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F9: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved. F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2027-03-10 | Direct | 70,258 |
Reported balance
After 2024-03-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-10 · Other · Disposed 23,419 · Balance 70,258 F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F11: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved. F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2024-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-10 · Exercise / conversion · Disposed 142,904 · Balance 0 F12: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter of market share units granted on March 10, 2020.
F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter of market share units granted on March 10, 2021.
F5: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award.
F6: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board.
F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
F9: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved.
F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date.
F11: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved.
F12: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return.
STRYKER CORP
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,530 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 762 · Balance 4,530 F1: Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027. F2: Each RSU represents a contingent right to receive one share of Stryker Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.
F2: Each RSU represents a contingent right to receive one share of Stryker Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2014 Filed Feb 25, 2014 21:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 1,976 | $54.59 | $107,869.84 |
DisclosureSEC source: 0000014272-14-000064 · wf-form4_139336382697784.xml · nonDerivative · entry 5 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,752.716 Read SEC document |
| February 24, 2014 Filed Feb 25, 2014 21:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 400 | $54.58 | $21,832.00 |
DisclosureSEC source: 0000014272-14-000064 · wf-form4_139336382697784.xml · nonDerivative · entry 4 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,728.716 Read SEC document |
| February 24, 2014 Filed Feb 25, 2014 21:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 12,572 | $54.57 | $686,054.04 |
DisclosureSEC source: 0000014272-14-000064 · wf-form4_139336382697784.xml · nonDerivative · entry 3 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,128.716 Read SEC document |
| February 24, 2014 Filed Feb 25, 2014 21:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 26,615 | $54.36 | $1,446,881.89 |
DisclosureSEC source: 0000014272-14-000064 · wf-form4_139336382697784.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,700.716 F1 · shares: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $54.35 to $54.39, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $54.35 to $54.39, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2014 Filed Feb 25, 2014 21:30 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 39,363 | $17.51 | $689,246.13 |
DisclosureSEC source: 0000014272-14-000064 · wf-form4_139336382697784.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,315.716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2014 Filed Jan 6, 2014 22:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000014 · wf-form4_138904801598968.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock, $0.10 par value · 7,500 shares Expires 2015-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| January 03, 2014 Filed Jan 6, 2014 22:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,864 | $52.85 | $151,362.40 |
DisclosureSEC source: 0000014272-14-000014 · wf-form4_138904801598968.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,952.716 F1 · shares: Shares withheld for payment of taxes upon vesting of resticted stock units. Read SEC document |
| January 03, 2014 Filed Jan 6, 2014 22:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-14-000014 · wf-form4_138904801598968.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,816.716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2013 Filed May 31, 2013 22:14 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 10,538 | $47.06 | $495,918.28 |
DisclosureSEC source: 0001225208-13-013596 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,316.219 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.05 to $47.09, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2013 Filed May 23, 2013 21:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 21,333 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0001225208-13-013159 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 21,333 shares Expires 2015-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 1, 2005. F2 · derivative.expiration_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 1, 2005. Read SEC document |
| May 23, 2013 Filed May 23, 2013 21:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 26,647 | $46.29 | $1,233,489.63 |
DisclosureSEC source: 0001225208-13-013159 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,854.219 F1 · shares: The reporting person sold 17,913 shares to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions upon the exercise of the option. The remaining 8,734 shares sold were held by the reporting person for more than a year. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.22 to $46.46, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: The reporting person sold 17,913 shares to cover the exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions upon the exercise of the option. The remaining 8,734 shares sold were held by the reporting person for more than a year. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $46.22 to $46.46, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2013 Filed May 23, 2013 21:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 21,333 | $25.45 | $542,924.85 |
DisclosureSEC source: 0001225208-13-013159 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,501.219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2013 Filed Mar 11, 2013 21:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 19,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007254 · doc4.xml · derivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,513 Underlying: Common Stock, $0.10 par value · 19,513 shares Expires 2017-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F2 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 277.292 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 21 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,224.292 Underlying: Common Stock, $0.10 par value · 277.292 shares Expires 2015-03-31 F19 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F20 · shares: Represents dividend equivalents earned under the 2012-2014 Long-Term Performance Award. F19 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. F19 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 6,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 20 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,947 Underlying: Common Stock, $0.10 par value · 6,947 shares Expires 2015-03-31 F17 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F18 · shares: Represents performance shares earned under the 2012-2014 Long-Term Performance Award. F17 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. F17 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2015. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 314.4128 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 19 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,191.4128 Underlying: Common Stock, $0.10 par value · 314.4128 shares Expires 2014-03-31 F15 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F16 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F15 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F15 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 3,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 18 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,877 Underlying: Common Stock, $0.10 par value · 3,553 shares Expires 2014-03-31 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F14 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F13 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 9,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 17 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 9,902 shares Expires 2013-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 377.8048 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 16 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,902 Underlying: Common Stock, $0.10 par value · 377.8048 shares Expires 2013-03-31 F11 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F12 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F11 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F11 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 2,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 15 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,524.1952 Underlying: Common Stock, $0.10 par value · 2,879 shares Expires 2013-03-31 F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F10 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 14 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock, $0.10 par value · 2,889 shares Expires 2016-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. F2 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 13 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197 Underlying: Common Stock, $0.10 par value · 1,197 shares Expires 2014-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · derivative · entry 12 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Common Stock, $0.10 par value · 1,494 shares Expires 2015-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F3 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,278 | $37.53 | $160,553.34 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 11 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,169.018 F7 · shares: Shares withheld for payment of taxes upon distribution of the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,225 | $37.53 | $45,974.25 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 10 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,447.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 802 | $37.53 | $30,099.06 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 9 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,672.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 667 | $37.53 | $25,032.51 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 8 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,474.018 F6 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 7 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,141.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 591 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 6 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,742.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 5 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,151.018 F5 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 4 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,493.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,296.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,802.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents vesting of one-quarter of market share units granted on March 6, 2012. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 07, 2013 Filed Mar 11, 2013 20:47 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 9,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-007236 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,913.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents distribution of performance shares earned under the 2010-2012 Long-Term Performance Award. Read SEC document |
| March 03, 2013 Filed Mar 5, 2013 21:26 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006626 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 1,851 shares Expires 2013-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. This is the final vesting of this award. F1 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. This is the final vesting of this award. Read SEC document |
| March 03, 2013 Filed Mar 5, 2013 21:26 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 690 | $37.15 | $25,633.50 |
DisclosureSEC source: 0001225208-13-006626 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,011.018 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| March 03, 2013 Filed Mar 5, 2013 21:26 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006626 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,701.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. This is the final vesting of this award. Read SEC document |
| February 27, 2013 Filed Feb 27, 2013 21:08 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 12,150 | $37.08 | $450,522.00 |
DisclosureSEC source: 0001225208-13-005725 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,850.018 Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $28.67 | $0.00 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 22,500 shares Expires 2014-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 2, 2004. Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 20,350 | $36.19 | $736,466.50 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000.018 F1 · shares: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.19 to $36.20, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.19 to $36.20, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 22,500 | $28.67 | $645,075.00 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,350.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, $0.10 par value · 7,500 shares Expires 2015-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,910 | $33.24 | $96,728.40 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,850.018 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,760.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2012 Filed Aug 28, 2012 20:07 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionOption (right to buy) · Derivative | 30,458 | $0.00 Strike: $23.18 | $0.00 |
DisclosureSEC source: 0001225208-12-018668 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 30,458 shares Expires 2013-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 4, 2003. Read SEC document |
| August 24, 2012 Filed Aug 28, 2012 20:07 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 25,900 | $32.69 | $846,671.00 |
DisclosureSEC source: 0001225208-12-018668 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,260.018 F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.67 to $32.71, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 24, 2012 Filed Aug 28, 2012 20:07 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 30,458 | $23.18 | $705,925.07 |
DisclosureSEC source: 0001225208-12-018668 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,160.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 186 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 9 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,324 Underlying: Common Stock, $0.10 par value · 186 shares Expires 2014-03-31 F13 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F14 · shares: Represents dividend equivalents earned under the 2011-2013 Long-Term Performance Award. F13 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. F13 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 4,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 8 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,138 Underlying: Common Stock, $0.10 par value · 4,138 shares Expires 2014-03-31 F11 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F12 · shares: Represents performance shares earned under the 2011-2013 Long-Term Performance Award. F11 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. F11 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2014. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 215.1952 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 7 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,645.1952 Underlying: Common Stock, $0.10 par value · 215.1952 shares Expires 2013-03-31 F9 · derivative.exercise_price: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F10 · shares: Represents dividend equivalents earned under the 2010-2012 Long-Term Performance Award. F9 · derivative.exercise_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. F9 · derivative.expiration_date: Each dividend equivalent converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.